Neurobiology of Aging 36 (2015) 149–156

Contents lists available at ScienceDirect

Neurobiology of Aging

journal homepage: www.elsevier.com/locate/neuaging

Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition

Maggie Roy [a,b,c,1], Cécile Cardoso [a,b,1], Olène Dorieux [a,b,d], Carole Malgorn [a,b], Stéphane Epelbaum [e,f,g,h,i], Fanny Petit [a,b], Audrey Kraska [a,b], Emmanuel Brouillet [a,b], Benoît Delatour [e,f,g,h,i], Martine Perret [d], Fabienne Aujard [d], Marc Dhenain [a,b,*]

[a] CEA, DSV, I2BM, MIRCen, URA CEA CNRS 2210, Fontenay aux Roses, France
[b] CNRS, URA 2210, Fontenay aux Roses, France
[c] Research Center on Aging, Université de Sherbrooke, Sherbrooke, Quebec, Canada
[d] CNRS UMR 7179, MNHN, Brunoy, France
[e] Sorbonne Universités, Paris, France
[f] UPMC Univ Paris 06 UMR S 1127, Paris, France
[g] Inserm, U 1127, Paris, France
[h] CNRS UMR 7225, Paris, France
[i] ICM, Paris, France

ARTICLE INFO

Article history:
Received 30 November 2012
Received in revised form 2 July 2014
Accepted 12 July 2014
Available online 18 July 2014

Keywords:
Amyloid
Alzheimer
Intracellular amyloid
Cerebral aging
Lemur
Microcebus murinus
Plasma

ABSTRACT

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. Amyloid-β peptide (Aβ) deposition in the brain is one of its hallmarks, and the measure of plasma Aβ is considered to be a biomarker for anti-amyloid drug efficacy in animal models of AD. However, age-associated plasmatic Aβ modulation in animal models is practically never addressed in the literature. Mouse lemur primates are used as a model of normal and AD-like cerebral aging. Here, we studied the effect of age on plasmatic Aβ in 58 mouse lemurs aged from 1 to 10 years. A subset of animals presented high plasmatic Aβ, and the proportion of animals with high plasmatic Aβ was higher in aged animals as compared with young ones. Histologic evaluation of the brain of some of these animals was carried out to assess extracellular and intracellular amyloid load. In aged lemurs, plasmatic Aβ was negatively correlated with the density of neurons accumulating deposits of Aβ.

1. Introduction

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. It is characterized by 2 main microscopic lesions: senile plaques and neurofibrillary tangles. Senile plaques are mainly constituted of aggregated extracellular deposition of amyloid-β (Aβ) peptides. These latter come from the proteolytic processing of the transmembrane amyloid-β precursor protein (APP) into mainly 2 types of Aβ peptides: $Aβ_{40}$ and $Aβ_{42}$. Neurofibrillary tangles are constituted of intraneuronal accumulation of abnormally phosphorylated tau proteins. The amyloid cascade hypothesis is currently the dominant explanation of AD etiology. It suggests that a chronic imbalance between production and clearance of Aβ peptides results in intracerebral accumulation of Aβ. This leads to a cascade of events that cause AD (Hardy and Selkoe, 2002; Sperling et al., 2011). In addition to senile plaques, Aβ is also present as soluble toxic oligomeric forms (Lacor et al., 2004; Selkoe, 2008) as well as intracellular Aβ deposits (Gouras et al., 2000; Gyure et al., 2001). The latter form occurs before plaque formation (Gyure et al., 2001; Wirths et al., 2001) and is also toxic for the brain (Wirths et al., 2004).

In humans, biomarkers of Aβ are used to facilitate AD diagnosis (Blennow et al., 2010; Jack et al., 2009) and evaluate the efficacy of anti-AD therapies (Relkin et al., 2009). The most widely used biochemical marker of Aβ is the measurement of $Aβ_{42}$ level in cerebrospinal fluid (CSF). Indeed, the concentration of $Aβ_{42}$ in CSF is lower in AD patients than in healthy control subjects (Andreasen et al., 1999). The decrease in CSF $Aβ_{42}$ in AD has been attributed, at least in part, to deposition of Aβ in plaques in the brain (Motter

* Corresponding author at: URA CEA CNRS 2210, 18 route du panorama, 92 265 Fontenay-aux-Roses cedex, France. Tel.: +33 1 46 54 81 92; fax: +33 1 46 54 84 51.
E-mail address: Marc.Dhenain@cea.fr (M. Dhenain).
[1] These authors contributed equally to the work.

0197-4580/$ – see front matter © 2015 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.neurobiolaging.2014.07.017

et al., 1995; Strozyk et al., 2003). Although measures of $A\beta_{42}$ in the CSF are widely used in the clinic, it is interesting to outline that $A\beta_{40}$ is the main Aβ component in the brain and in peripheric fluids and the concentration of $A\beta_{40}$ in the CSF is assumed to reflect the total amount of Aβ proteins in the brain (Wiltfang et al., 2007). Also, recent studies suggested that including measurement of CSF $A\beta_{40}$ levels in a decision tree can help to better discriminate patients with AD in ambiguous clinical diagnosis cases (Sauvee et al., 2014; Slaets et al., 2013).

As plasma sampling is simpler and less invasive than a lumbar puncture, several authors have investigated the ability to use plasmatic Aβ as an alternative to measurements in CSF. The published data on plasma Aβ from single cross-sectional studies in humans are however still conflicting: plasma Aβ of AD patients have been reported to be higher, lower, or unchanged as compared with control subjects (Buerger et al., 2009; Roher et al., 2009; Sobow et al., 2005). However, a meta-analysis recently suggested higher baseline plasma $A\beta_{40}$ and $A\beta_{42}$ in cognitively normal subjects who converted to AD (Song et al., 2011). Then when AD develops, plasmatic $A\beta_{42}$ declines (Song et al., 2011). Also, direct evaluation of relationships between plasma Aβ loads and intracerebral amyloid load measures by imaging methods have revealed a positive relationship between plasma $A\beta_{40}$ levels and cerebral amyloid load and a negative relationship between Aβ42 to Aβ40 ratio and cerebral amyloid load (Devanand et al., 2011). In addition to AD, other factors such as aging have been reported to increase baseline plasma Aβ in humans (Lopez et al., 2008). In addition to its potential use for AD diagnosis, one possible application of measures of plasmatic Aβ is the evaluation of target engagements for therapies modulating Aβ synthesis. For example, treatments with γ-secretase inhibitors are shown to reduce the level of $A\beta_{40}$ in the plasma (Fleisher et al., 2008).

Animal models are widely used to discover fundamental mechanisms associated to AD pathology and evaluate new drugs against AD. Transgenic mouse models of amyloidosis expressing mutant forms of human APP and presenilin 1 (Duyckaerts et al., 2008) and spontaneous models of brain aging such as primates (Picq et al., 2012) are the most widely used models to study various aspects of AD pathology and therapy. As in humans, Aβ modulation in animal models can be evaluated in the CSF (Das et al., 2011; Liu and Duff, 2008). In small animals, Aβ can be measured more easily in the plasma. These measurements are used to evaluate the effects of various biological factors such as APOE genotype on Aβ clearance (Sharman et al., 2010) or to assess therapeutic effects of potential drugs. For example, studies in transgenic mouse models of AD have shown that treatments with γ- or β-secretase inhibitors reduce plasmatic $A\beta_{42}$ and $A\beta_{40}$ (Chang et al., 2004; Kounnas et al., 2010; Lanz et al., 2010). Modulation of plasmatic Aβ can also be used to follow-up the effects of anti-Aβ immunotherapies in mice (Lemere, 2009; Wang et al., 2011; Yamada et al., 2009). Studies of therapeutic interventions in primates also revealed changes in plasmatic Aβ. For example, increased plasmatic Aβ is detected following active immunotherapy in primates such as the mouse lemur (Joseph-Mathurin et al., 2013; Trouche et al., 2009) and the caribbean vervet (Lemere et al., 2004).

Few studies in animal models have focused on the modulation of plasmatic Aβ during aging. Studies in the Tg2576 transgenic mice, a model that develops Aβ plaques at 12 months, suggested constant plasma Aβ until 12 months of age, after what, an age-associated decrease in plasma Aβ was detected in coincidence with the marked cerebral deposition of Aβ (Kawarabayashi et al., 2001). Another study in dogs showed higher plasmatic Aβ in young animals as compared with old cognitively unimpaired animals and higher Aβ in old animals with mild cognitive impairment as compared with either cognitively unimpaired or severely affected dogs (Gonzalez-Martinez et al., 2011). To the best of our knowledge, age-associated modulation of plasmatic Aβ has never been addressed in non-human primates. The aim of the present study was thus to evaluate the effect of age on plasmatic Aβ in the mouse lemur primate (*Microcebus murinus*). This small primate (70–150g) has a short life span of approximately 12 years. A subcategory of aged lemurs can develop both extracellular (Bons et al., 1991) and intracellular (Joseph-Mathurin et al., 2013; Mestre-Frances et al., 2000) Aβ deposits and tau pathologies (Kraska et al., 2011). Our results suggest increased plasmatic Aβ levels in a subpopulation of aged lemurs. We also show that a high plasmatic Aβ in aged animals is associated to a low level of intraneuronal material detected by the 4G8 monoclonal antibody and that corresponds to Aβ accumulation.

2. Methods

2.1. Animals

Fifty-eight mouse lemurs were involved in the present study, n = 25 young animals (1–5.5 years) and n = 33 aged animals (5.5–10 years). They were all born in a laboratory breeding colony (Brunoy, France, Agreement n°E91-114-1). All experiments were carried out in accordance with European Communities Council directive (86/609/EEC) under the authorization number 91–326 from the "Direction Départementale des Services Vétérinaires de l'Essonne" and the Internal Review Board of the URA CEA CNRS 2210.

2.2. Blood collection, pretreatment, and plasmatic Aβ detection

Blood was collected from the saphenous vein. The vein was pricked with a needle at a 45° angle and blood was collected in small heparinised capillaries (60 μL). Every blood sampling was done at the same time in the morning. All blood samples were kept on ice and centrifuged (2000*g*, 10 minutes) at 4 °C in the 15 minutes following the collection. The plasma layer was then collected in 200 μL polypropylene tubes. A cocktail of proteases inhibitors (Complete Mini; Roche, Meylan, France) was added to each plasma sample at a final concentration of 1X. The samples were then allowed to freeze in a −80 °C freezer and were then kept at −80 °C until their analysis.

Plasmatic level of $A\beta_{40}$ was assessed with enzyme-linked immunosorbent assay (ELISA) kits "Human β amyloid 1-40" (Invitrogen, Saint Aubin, France). The ELISA was carried out following the manufacturer's protocol and executed using non-diluted plasma samples.

2.3. Brain tissue processing and immunohistochemical staining

The brains of 7 aged mouse lemurs with known concentration of plasmatic Aβ were removed and fixed in 4% formalin after the natural death of animals. Brains were plunged in a 15% sucrose solution for 24 hours and then in a 30% sucrose solution for cryoprotection. They were then frozen and sliced into 40-μm-thick coronal sections on a freezing microtome. Slices were then stored at −20 °C in a storage solution (glycerol 30%, ethylene glycol 30%, and phosphate buffer 0.1 M).

Brains sections from all studied animals were first immunostained using the 4G8 antibody directed against the residues 17–24 of Aβ. The 4G8 antibody is routinely used to detect amyloid deposits (Alafuzoff et al., 2008). Sections were pretreated with hydrogen peroxide (0.3%), then incubated in a phosphate buffered (0.1 M), saline (0.9%), and triton (0.2%) solution (PBS + Tx) with normal goat serum (NGS; 4.5%). Sections were then incubated for 2 days into PBS + Tx solution with NGS (3%) and the primary antibody mouse monoclonal 4G8 antibody; 1/500; Covance Signet Antibodies, Debham, MA, USA). Sections were incubated for 1 hour into a PBS +

Tx solution with NGS (3%) and the secondary antibody (biotinylated goat anti-mouse antibody; 1/1000; Vector Laboratories, Burlingame, CA, USA). The signal was amplified using an avidin-biotin complex for 1 hour (Vectastain, Vector Laboratories). The final reaction used diaminobenzidine (DAB; Vector Laboratories) for 2 minutes as the chromogen (brown stains). Counterstaining with cresyl violet was used to distinguish cells nuclei. Negative controls were performed by omitting the primary antibody in the procedure. Positive controls were performed using formalin-fixed brain sections of APP/PS1dE9 mice (Garcia-Alloza et al., 2006). All sections were mounted on slides and viewed using a standard microscope (Zeiss Axioplan, Germany).

As 4G8 cross-reacts with APP (Aho et al., 2010), we performed control experiments to assess the specificity of 4G8 immunostaining. We carried out double immunofluorescent staining (n = 5 animals) with a cocktail of primary antibodies: 4G8 (1/5000) and A8717, a polyclonal antibody directed against the amino acids 676-695 of the C-terminus part of the APP (1/500, Sigma-Aldrich, St Louis, MO, USA). Primary antibodies were incubated overnight at room temperature. Detection-visualization of primary antibodies was performed using a cocktail of secondary antibodies: Goat anti-Mouse Fluor Hylite 555 (1/200, Jackson Immunoresearch, West Grove, PA, USA) to detect 4G8 and donkey anti-Rabbit antibody conjugated to an Alexa Fluor 488 (1/200; Invitrogen) to detect A8717. Sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and treated for 30 seconds in a saturated Sudan Black solution to decrease a specific autofluorescence (Delatour et al., 2001).

2.4. Morphologic analysis

Intracellular 4G8 positive deposits, revealed by immunoperoxidase stainings, were detected mainly in the parietal cortex, hippocampus, and in the caudate nucleus (see Section 3). The optical fractionator method was used to quantify the deposit-positive cells in these regions (West et al., 1991). Aggregate-positive cells were counted using a Zeiss Axioplan microscope equipped with a digital color camera, x–y motorized stage controller, and Mercator (ExploraNova) stereology software. The regions of interest were delineated using a 1.5× objective, in accordance with a mouse lemur brain atlas (Bons et al., 1998). Sampling was performed bilaterally within the delineated areas with a 20× objective. The analysis was done on slices spaced out of 800 μm. Analysis was performed from squares sampling the structure (14.8% of the surface). The density of cells presenting intracellular aggregates (number of cells per mm^2 of surface sampled) was calculated.

For the purpose of control experiments colocalization of 4G8-positive intracellular objects and A8717-positive objects were assessed in the caudate nucleus. The analysis was performed on 5 animals with ImageJ and the JACOP plugin (Bolte and Cordelieres, 2006). We studied the cytofluorograms and calculated a mean Pearson and overlap coefficient for all neurons exhibiting both 4G8 and/or A8717 signals.

2.5. Statistical analysis

Spearman test was used to evaluate the correlation between plasmatic Aβ and age or cerebral 4G8 positive objects. χ^2 test was used to compare the proportion of animals with low and high plasma Aβ in young and aged animals. Student t test was used to perform group comparisons. Statistical analysis was made using PRISM 5 software (Graphpad, La Jolla, CA, USA). p-value < 0.05 was set as statistically significant level for each test.

3. Results

3.1. Plasmatic Aβ

Plasmatic Aβ was evaluated in 1- to 10-year-old mouse lemurs. No significant correlation was noted between plasmatic $A\beta_{40}$ and age (Fig. 1A). However, a large heterogeneity was observed in aged animals, as compared with young ones. Indeed, when we separated plasma Aβ in 2 categories: low level (≤55 pg/mL) and high level (>55 pg/mL), we found a significantly larger number of aged animals with a high plasma Aβ as compared with young animals (43 vs. 16 % of the old and young animals, respectively; $X^2 = 4.64$; $p = 0.031$). The concentrations of plasma Aβ in the animals classified as low or high plasma Aβ levels were significantly different (mean ± standard error of the mean = 36.2 ± 1.5 pg/mL and 86.7 ± 7.9 pg/mL, Student t test, $p < 0.0001$, respectively).

3.2. Neuropathology

The brains of 7 aged animals (6.1–9.3 years old) studied for plasmatic Aβ could be evaluated by neuropathology (4 animals had low plasmatic Aβ (Fig. 1A, green dots) and 3 had high plasma Aβ (Fig. 1A, red dots). Extracellular Aβ deposits were observed in the cortex of only 1 of the 7 aged animals analyzed (Fig. 2H). It was an 8-year-old animal with a high concentration of plasmatic Aβ (59.9 pg/mL). The 2 other animals with high plasmatic Aβ (127.5 and 63.5 pg/mL) did not have plaques. In all the animals, 4G8-positive objects were mainly observed in the form of intracellular deposits (Fig. 2C–G). These deposits were present in several brain regions such as the parietal cortex, hippocampus, caudate nucleus, and in a ventral brain areas corresponding to the nucleus basalis of Meynert (Bons et al., 1998). They appeared as an accumulation of spherical vesicles within the cells (Fig. 2A–G, Fig. 3A–B). The density of vesicles varied within the cells: the vesicles density could be low (Fig. 2G, label 1); it could be higher, providing an aspect of diffuse deposition (Fig. 2G, label 2); in some cases, the vesicles were densely packed within the cells (Fig. 2G, label 3). Overall, the densely packed deposits were less numerous than the less packed more diffuse deposits.

The 4G8 positive objects were found in the same brain locations regardless of the immunostaining method (immunoperoxidase or immunofluorescence). No fluorescent staining could be detected in sections incubated without primary antibodies, indicating the absence of confounding autofluorescent background that may interfere with the analysis of double staining. Immunodetection of APP with the A8717 antibody revealed intracellular staining of numerous neurons in almost all brain regions. APP immunostaining was hence not exclusively observed in the neurons displaying 4G8 immunoreactivity (Fig. 3A). In the caudate nucleus, 445 cells were randomly selected for APP/4G8 co-labeling analysis. Of these 396 neurons (i.e., 89%) were A8717-positive and 4G8-negative (Fig. 3A), whereas only 9 neurons (2%) of the sampled population were A8717-negative and 4G8-positive (Fig. 3A). Nine percent (40/445) of the neurons were both A8717-positive and 4G8-positive; however, in this subpopulation of double-stained neurons the intracellular topographies of A8717 and 4G8 immunostainings were different and poorly colocalized: low overlap coefficients were indeed observed between 4G8 and A8717 signals ($r = 0.569$, 95% CI 0.528–0.621) in the 5 studied animals (Fig. 3C). These results showed that, in our experimental conditions, 4G8 immunostaining does not cross-react with APP and therefore points to local accumulations of Aß.

In the 3 quantified brain regions, the 4G8-positive cells were more numerous in the animals with low plasma amyloid load as compared with animals with high plasma amyloid load (Fig. 1B). Interestingly, the total number of 4G8-positive cells in the caudate



Fig. 1. (A) Plasma $A\beta_{40}$ in mouse lemurs primates (n = 25 young animals [1–5.5 years] and n = 33 aged animals [5.5–10 years]). Aβ levels were classified either as low (≤55 pg/mL; dark or green spots) or high levels (>55 pg/mL; white or red spots). A larger number of animals older than 5.5 years had a high Aβ level as compared with young animals. The green and red spots correspond to animals that were studied by histology. The yellow ring corresponds to an animal that had extracellular amyloid deposits. (B) Number of neurons presenting intracellular Aβ positive profiles in the caudate, parietal cortex, and hippocampus of animals with low and high plasmatic Aβ loads (data represent mean ± SEM). (C) Plot fitting plasmatic Aβ and the density of intracellular Aβ aggregates in the caudate of aged animals. The values on the side of the dots are ages of the animals at blood sampling. The curve represents a logarithmic fit between intracellular Aβ and plasmatic Aβ. A significant negative correlation was found between intracellular Aβ and plasmatic Aβ ($r = -0.86$, $p < 0.05$). Abbreviations: Aβ, amyloid-β; SEM, standard error mean. (For interpretation of the references to color in this figure, the reader is referred to the web version of this article.)

nucleus was negatively correlated to plasmatic $A\beta_{40}$ (Fig. 1C; $r = -0.86$, $p < 0.05$).

4. Discussion

Plasma Aβ is used as a biomarker for drug efficiency studies in animal models of AD (Chang et al., 2004; Kounnas et al., 2010; Lanz et al., 2010). However, age-associated plasmatic Aβ modulation in animal models is practically never addressed in the literature. Also data on evolution of plasma Aβ during aging and AD in humans are still controversial (Buerger et al., 2009; Roher et al., 2009; Sobow et al., 2005; Song et al., 2011). Assessing the effect of age and pathology progression on plasmatic Aβ in primate models is thus a crucial issue. Here, we evaluated plasmatic Aβ in mouse lemur primates, a model of cerebral aging that can spontaneously develop intracellular (Joseph-Mathurin et al., 2013; Mestre-Frances et al., 2000) and extracellular (Bons et al., 1991) Aβ deposits while aging. In mouse lemurs, plasma Aβ is already used as a biomarker in drug studies (Joseph-Mathurin et al., 2013; Trouche et al., 2009) although the age effect on plasmatic Aβ has never been studied. In mouse lemurs, plasma Aβ concentrations are much lower than in transgenic mice, as mouse lemurs are non transgenic animals who are not overexpressing Aβ. Because of the low plasma Aβ concentration in lemurs, $A\beta_{42}$ levels are usually below the limit of detection with classical ELISA tests (Trouche et al., 2009). We thus focused on $A\beta_{40}$ that is the main Aβ component in the brain. In humans $A\beta_{40}$ in the CSF is assumed to reflect the total amount of Aβ proteins in the brain (Wiltfang et al., 2007), and a positive relationship has been reported between plasma $A\beta_{40}$ levels and cerebral amyloid load measured by imaging methods (Devanand et al., 2011). $A\beta_{40}$ in the plasma is also used to follow-up the action of drugs modulating Aβ synthesis or promoting amyloid clearance in animals (Chang et al., 2004; Lanz et al., 2010; Trouche et al., 2009) and humans (Fleisher et al., 2008). Interestingly, as opposed to transgenic mice (data not shown), we found 2 categories of aged mouse lemurs: low (57%) and high (43%) plasmatic Aβ (Fig. 1A). This suggests that in lemurs, Aβ is modulated differently among animals with aging.

Only 1 animal of the 7 lemurs evaluated by histology, displayed extracellular Aβ plaques. This animal had high plasma Aβ. However, the other animals with higher plasmatic Aβ did not show any extracellular Aβ deposits. Extracellular deposits were not found in mouse lemurs with low plasma Aβ. This possibly suggests a lack of correlation between these 2 parameters. However, as the number of extracellular deposits is very rare in mouse lemurs, the number of animals included in our histologic evaluation is likely too low to establish such a correlation.

Strikingly, intracellular accumulation of 4G8 positive material was detected in all studied animals (with density of intraneuronal staining varying from one case to the other). We selected the 4G8 antibody to immunodetect intraneuronal deposits as it is a standard antibody used in animal and human tissues to reveal Aß deposition. 4G8 immunohistochemistry is even considered as a reference



Fig. 2. Aβ deposits in brain tissues of aged mouse lemurs (4G8 staining). (A–F) Comparison of Aβ deposits in animals with low (A, C, and E) and high (B, D, and F) plasmatic amyloid load. (A and B) Low-resolution image showing the caudate (cd), corpus callosum (cc), and internal capsula (ci). (C–F) Higher-magnification images showing intracellular amyloid deposits (arrows) in the caudate. (G) High-magnification image processed with the 3D mode algorithm of exploranova software showing various types of intracellular deposits: spherical vesicles with a low density (1); spherical vesicles with an increased density providing an aspect of diffuse deposition (2); and densely packed vesicles (3). (H) Extracellular amyloid plaques as seen in the cortex of only 1 animal (arrows). Scale bars: A, B and H: 200 μm and C–G: 50 μm. Abbreviation: Aβ, amyloid-β. (For interpretation of the references to color in this figure, the reader is referred to the web version of this article.)



Fig. 3. Identification of the nature of the 4G8-positive intracellular deposits. (A and B) Immunofluorescent stained sections showing the location of 4G8 (red) and A8717-positive (green) objects. (A) Example showing cells labeled only with 4G8 or with A8717 (arrows). (B) Example showing different locations of 4G8 and A8717-positive objects within the same neuron (arrows). (C) The overlap coefficients were low between objects detected by the 4G8 or the A8717 antibodies (C). Scale bars = 10 μm. (For interpretation of the references to color in this figure, the reader is referred to the web version of this article.)

method for multicentric studies (Alafuzoff et al., 2008) and for the standardization of neuropathological assessment of brain amyloidosis (Alafuzoff et al., 2009). However, because of epitope specificity 4G8 can cross-react with APP. The presence of Aß in neurons is currently highly discussed. It can be clearly evidenced in neuronal cell cultures (Lee et al., 2003) and also in a few AD transgenic mouse lines with very aggressive neuropathology, such as the APPxPS1-Ki and 5xFAD models (Faure et al., 2011; Oakley et al., 2006). However, the presence of Aß in neurons of AD mice remains a matter of debate (Cuello et al., 2012; Winton et al., 2011; Wirths et al., 2012).

Results from our double labeling control experiments revealed that, in mouse lemurs, 4G8-positive intracellular objects do not strictly correspond to APP accumulation. It can be concluded that 4G8 objects in mouse lemurs are mainly composed of Aβ and not of APP. Intracellular Aβ deposition is often considered as an early stage of the evolution toward AD either in experimental models (Casas et al., 2004; Walsh et al., 2000) or in humans (Gouras et al., 2000). Interestingly, intracellular Aβ vanishes as extracellular Aβ deposition increases (Wirths et al., 2001). This suggests that it is released in the extracellular space before to aggregate in extracellular Aβ deposits. Also, there is a balance between the soluble extracellular Aβ in the brain and in the plasma (Craft et al., 2002). Our data may support a 3-phases model of amyloidosis development: (1) a low plasmatic amyloid load can be associated either to a low amyloid synthesis which may be the case in young animals and in some aged animals, or to the sequestration of Aβ in the intra-neuronal space, as seen in the old animals included in our study; (2) then, Aβ is released in the extracellular space from where it is exported to the periphery increasing plasma concentration. This would explain the high plasma Aβ levels found in animals with a low intracellular amyloid load; (3) Data from the literature suggest that later the extracellular Aβ may also aggregate into parenchymal Aβ plaques leading to a reduced plasma Aβ (Song et al., 2011). The phases 1 and 2 of this process match with our observations in lemurs and could explain some findings reported in humans (Song et al., 2011) and dogs (Gonzalez-Martinez et al., 2011) underlining an increased plasmatic Aβ in early phases of AD or of AD-like age-related pathologies. These events could correspond to a time frame during which amyloid can be released from cells but is not yet aggregated into plaques, hence favoring its passage to the plasmatic compartment.

Other factors could however explain plasmatic Aβ modulation in our animals. In humans, it was proposed that plasmatic Aβ pool does not only result from intracerebral Aβ clearance, but also from peripheral sources such as the skeletal muscle, platelets, and vascular walls, which produce appreciable amounts of Aβ (Kuo et al., 2000). Also, some plasma proteins such as immunoglobulins, apolipoproteins, and proteins of the complement can bind and mask Aβ peptides or can modulate their metabolism (Roher et al., 2009). Pathologic states such as atherosclerotic vascular diseases can also modulate the bioavailability of peripheral Aβ, which appears to bind fatty streaks in atherosclerotic vessels (Roher et al., 2009). We cannot rule out a role of these factors in the regulation of plasma Aβ in lemurs. Finally, plasmatic Aβ in lemurs could also be regulated by internal factors such as corticoid levels. Indeed, a study in macaques has shown that plasmatic Aβ is reduced by chronic exposure to corticoids (Kulstad et al., 2005). Environmental factors leading to stress and increased glucocorticoid levels might thus also modulate plasmatic Aβ in lemurs. Longitudinal studies will thus have to be performed to further elucidate the origin of plasmatic Aβ pool and to study the reason of heterogeneous plasmatic Aβ in old lemurs. However, our results suggest that in aged animals plasmatic Aβ can be used as a stratification biomarker to include homogeneous animals in experimental groups for preclinical drug trials that aim at modifying amyloid load.

Disclosure statement

The authors declare no conflicts of interest.

Acknowledgements

This study was financially supported by the Association France Alzheimer, the National Foundation for Alzheimer's Disease and

Related Disorders, and the National Institute on Aging (R01-AG020197). The authors thank Marion Chaigneau, Diane Houitte, and Martine Guillermier for their technical assistance.

References

Aho, L., Pikkarainen, M., Hiltunen, M., Leinonen, V., Alafuzoff, I., 2010. Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. J. Alzheimers Dis. 20, 1015–1028.

Alafuzoff, I., Pikkarainen, M., Arzberger, T., Thal, D.R., Al-Sarraj, S., Bell, J., Bodi, I., Budka, H., Capetillo-Zarate, E., Ferrer, I., Gelpi, E., Gentleman, S., Giaccone, G., Kavantzas, N., King, A., Korkolopoulou, P., Kovacs, G.G., Meyronet, D., Monoranu, C., Parchi, P., Patsouris, E., Roggendorf, W., Stadelmann, C., Streichenberger, N., Tagliavini, F., Kretzschmar, H., 2008. Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe Consortium. Acta Neuropathol. 115, 533–546.

Alafuzoff, I., Thal, D.R., Arzberger, T., Bogdanovic, N., Al-Sarraj, S., Bodi, I., Boluda, S., Bugiani, O., Duyckaerts, C., Gelpi, E., Gentleman, S., Giaccone, G., Graeber, M., Hortobagyi, T., Hoftberger, R., Ince, P., Ironside, J.W., Kavantzas, N., King, A., Korkolopoulou, P., Kovacs, G.G., Meyronet, D., Monoranu, C., Nilsson, T., Parchi, P., Patsouris, E., Pikkarainen, M., Revesz, T., Rozemuller, A., Seilhean, D., Schulz-Schaeffer, W., Streichenberger, N., Wharton, S.B., Kretzschmar, H., 2009. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol. 117, 309–320.

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., Blennow, K., 1999. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 56, 673–680.

Blennow, K., Hampel, H., Weiner, M., Zetterberg, H., 2010. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131–144.

Bolte, S., Cordelieres, F.P., 2006. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 224, 213–232.

Bons, N., Mestre, N., Petter, A., 1991. Senile plaques and neurofibrillary changes in the brain of an aged lemurian primate, *Microcebus murinus*. Neurobiol. Aging 13, 99–105.

Bons, N., Sihol, S., Barbier, V., Mestre-Frances, N., Albe-Fessard, D., 1998. A stereotaxic atlas of the grey lesser mouse lemur brain (*Microcebus murinus*). Brain Res. Bull. 46, 1–173.

Buerger, K., Frisoni, G., Uspenskaya, O., Ewers, M., Zetterberg, H., Geroldi, C., Binetti, G., Johannsen, P., Rossini, P.M., Wahlund, L.O., Vellas, B., Blennow, K., Hampel, H., 2009. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp. Gerontol. 44, 579–585.

Casas, C., Sergeant, N., Itier, J.M., Blanchard, V., Wirths, O., van der Kolk, N., Vingtdeux, V., van de Steeg, E., Ret, G., Canton, T., Drobecq, H., Clark, A., Bonici, B., Delacourte, A., Benavides, J., Schmitz, C., Tremp, G., Bayer, T.A., Benoit, P., Pradier, L., 2004. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 165, 1289–1300.

Chang, W.P., Koelsch, G., Wong, S., Downs, D., Da, H., Weerasena, V., Gordon, B., Devasamudram, T., Bilcer, G., Ghosh, A.K., Tang, J., 2004. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J. Neurochem. 89, 1409–1416.

Craft, D.L., Wein, L.M., Selkoe, D.J., 2002. A mathematical model of the impact of novel treatments on the Abeta burden in the Alzheimer's brain, CSF and plasma. Bull. Math. Biol. 64, 1011–1031.

Cuello, A.C., Allard, S., Ferretti, M.T., 2012. Evidence for the accumulation of Abeta immunoreactive material in the human brain and in transgenic animal models. Life Sci. 91, 1141–1147.

Das, R., Nachbar, R.B., Edelstein-Keshet, L., Saltzman, J.S., Wiener, M.C., Bagchi, A., Bailey, J., Coombs, D., Simon, A.J., Hargreaves, R.J., Cook, J.J., 2011. Modeling effect of a gamma-secretase inhibitor on amyloid-beta dynamics reveals significant role of an amyloid clearance mechanism. Bull. Math. Biol. 73, 230–247.

Delatour, B., Mercken, L., El Hachimi, K.H., Colle, M.A., Pradier, L., Duyckaerts, C., 2001. FE65 in Alzheimer's disease: neuronal distribution and association with neurofibrillary tangles. Am. J. Pathol. 158, 1585–1591.

Devanand, D.P., Schupf, N., Stern, Y., Parsey, R., Pelton, G.H., Mehta, P., Mayeux, R., 2011. Plasma Abeta and PET PiB binding are inversely related in mild cognitive impairment. Neurology 77, 125–131.

Duyckaerts, C., Potier, M.C., Delatour, B., 2008. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 115, 5–38.

Faure, A., Verret, L., Bozon, B., El Tannir El Tayara, N., Ly, M., Kober, F., Dhenain, M., Rampon, C., Delatour, B., 2011. Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease. Neurobiol. Aging 32, 407–418.

Fleisher, A.S., Raman, R., Siemers, E.R., Becerra, L., Clark, C.M., Dean, R.A., Farlow, M.R., Galvin, J.E., Peskind, E.R., Quinn, J.F., Sherzai, A., Sowell, B.B., Aisen, P.S., Thal, L.J., 2008. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031–1038.

Garcia-Alloza, M., Robbins, E.M., Zhang-Nunes, S.X., Purcell, S.M., Betensky, R.A., Raju, S., Prada, C., Greenberg, S.M., Bacskai, B.J., Frosch, M.P., 2006. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24, 516–524.

Gonzalez-Martinez, A., Rosado, B., Pesini, P., Suarez, M.L., Santamarina, G., Garcia-Belenguer, S., Villegas, A., Monleon, I., Sarasa, M., 2011. Plasma beta-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease. Exp. Gerontol. 46, 590–596.

Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J.P., Haroutunian, V., Buxbaum, J.D., Xu, H., Greengard, P., Relkin, N.R., 2000. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 156, 15–20.

Gyure, K.A., Durham, R., Stewart, W.F., Smialek, J.E., Troncoso, J.C., 2001. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 125, 489–492.

Hardy, J., Selkoe, D.J., 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356.

Jack Jr., C.R., Lowe, V.J., Weigand, S.D., Wiste, H.J., Senjem, M.L., Knopman, D.S., Shiung, M.M., Gunter, J.L., Boeve, B.F., Kemp, B.J., Weiner, M., Petersen, R.C., 2009. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355–1365.

Joseph-Mathurin, N., Dorieux, O., Trouche, S., Boutajangout, A., Kraska, A., Fontès, P., Verdier, J.-M., Sigurdsson, E.M., Mestre-Francés, N., Dhenain, M., 2013. Aβ immunization in old mouse lemur primates induces cerebral microhemorrhages and accelerates age-associated iron deposits in the choroid plexus. Neurobiol. Aging 34, 2613–2622.

Kawarabayashi, T., Younkin, L.H., Saido, T.C., Shoji, M., Ashe, K.H., Younkin, S.G., 2001. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372–381.

Kounnas, M.Z., Danks, A.M., Cheng, S., Tyree, C., Ackerman, E., Zhang, X., Ahn, K., Nguyen, P., Comer, D., Mao, L., Yu, C., Pleynet, D., Digregorio, P.J., Velicelebi, G., Stauderman, K.A., Comer, W.T., Mobley, W.C., Li, Y.M., Sisodia, S.S., Tanzi, R.E., Wagner, S.L., 2010. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67, 769–780.

Kraska, A., Dorieux, O., Picq, J.-L., Petit, F., Bourrin, E., Chenu, E., Volk, A., Perret, M., Hantraye, P., Mestre-Frances, N., Aujard, F., Dhenain, M., 2011. Age associated cerebral atrophy in mouse lemur primates. Neurobiol. Aging 32, 894–906.

Kulstad, J.J., McMillan, P.J., Leverenz, J.B., Cook, D.G., Green, P.S., Peskind, E.R., Wilkinson, C.W., Farris, W., Mehta, P.D., Craft, S., 2005. Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. J. Neuropathol. Exp. Neurol. 64, 139–146.

Kuo, Y.M., Kokjohn, T.A., Watson, M.D., Woods, A.S., Cotter, R.J., Sue, L.I., Kalback, W.M., Emmerling, M.R., Beach, T.G., Roher, A.E., 2000. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am. J. Pathol. 156, 797–805.

Lacor, P.N., Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Velasco, P.T., Bigio, E.H., Finch, C.E., Krafft, G.A., Klein, W.L., 2004. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24, 10191–10200.

Lanz, T.A., Wood, K.M., Richter, K.E., Nolan, C.E., Becker, S.L., Pozdnyakov, N., Martin, B.A., Du, P., Oborski, C.E., Wood, D.E., Brown, T.M., Finley, J.E., Sokolowski, S.A., Hicks, C.D., Coffman, K.J., Geoghegan, K.F., Brodney, M.A., Liston, D., Tate, B., 2010. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. J. Pharmacol. Exp. Ther. 334, 269–277.

Lee, E.B., Skovronsky, D.M., Abtahian, F., Doms, R.W., Lee, V.M., 2003. Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. J. Biol. Chem. 278, 4458–4466.

Lemere, C.A., 2009. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog. Brain Res. 175, 83–93.

Lemere, C.A., Beierschmitt, A., Iglesias, M., Spooner, E.T., Bloom, J.K., Leverone, J.F., Zheng, J.B., Seabrook, T.J., Louard, D., Li, D., Selkoe, D.J., Palmour, R.M., Ervin, F.R., 2004. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol. 165, 283–297.

Liu, L., Duff, K., 2008. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J. Vis. Exp. e960. http://www.jove.com/index/Details.stp?ID=960.

Lopez, O.L., Kuller, L.H., Mehta, P.D., Becker, J.T., Gach, H.M., Sweet, R.A., Chang, Y.F., Tracy, R., DeKosky, S.T., 2008. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70, 1664–1671.

Mestre-Frances, N., Keller, E., Calenda, A., Barelli, H., Checler, F., Bons, N., 2000. Immunohistochemical analysis of cerebral cortical and vascular lesions in the primate Microcebus murinus reveal distinct amyloid beta 1-42 and beta 1-40 immunoreactivity profiles. Neurobiol. Dis. 7, 1–8.

Motter, R., Vigo-Pelfrey, C., Kholodenko, D., Barbour, R., Johnson-Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., Olson, D., Southwick, P., Wolfert, R., Munroe, B., Lieberburg, I., Seubert, P., Schenk, D., 1995. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38, 643–648.

Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R., Vassar, R., 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129–10140.

Picq, J.L., Aujard, F., Volk, A., Dhenain, M., 2012. Age-related cerebral atrophy in nonhuman primates predicts cognitive impairments. Neurobiol. Aging 33, 1096–1109.

Relkin, N.R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R.W., Younkin, S., Younkin, L., Schiff, R., Weksler, M.E., 2009. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30, 1728–1736.

Roher, A.E., Esh, C.L., Kokjohn, T.A., Castano, E.M., Van Vickle, G.D., Kalback, W.M., Patton, R.L., Luehrs, D.C., Daugs, I.D., Kuo, Y.M., Emmerling, M.R., Soares, H., Quinn, J.F., Kaye, J., Connor, D.J., Silverberg, N.B., Adler, C.H., Seward, J.D., Beach, T.G., Sabbagh, M.N., 2009. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 5, 18–29.

Sauvee, M., DidierLaurent, G., Latarche, C., Escanye, M.C., Olivier, J.L., Malaplate-Armand, C., 2014. Additional use of abeta42/abeta40 ratio with cerebrospinal fluid biomarkers p-tau and abeta42 increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. J. Alzheimers Dis. 41, 377–386.

Selkoe, D.J., 2008. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106–113.

Sharman, M.J., Morici, M., Hone, E., Berger, T., Taddei, K., Martins, I.J., Lim, W.L., Singh, S., Wenk, M.R., Ghiso, J., Buxbaum, J.D., Gandy, S., Martins, R.N., 2010. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. J. Alzheimers Dis. 21, 403–409.

Slaets, S., Le Bastard, N., Martin, J.J., Sleegers, K., Van Broeckhoven, C., De Deyn, P.P., Engelborghs, S., 2013. Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J. Alzheimers Dis. 36, 759–767.

Sobow, T., Flirski, M., Kloszewska, I., Liberski, P.P., 2005. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol. Exp. 65, 117–124.

Song, F., Poljak, A., Valenzuela, M., Mayeux, R., Smythe, G.A., Sachdev, P.S., 2011. Meta-analysis of plasma amyloid-beta levels in Alzheimer's disease. J. Alzheimers Dis. 25, 1–11.

Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., Iwatsubo, T., Jack, C.R., Kaye, J., Montine, T.J., Park, D.C., Reiman, E.M., Rowe, C.C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M.C., Thies, B., Morrison-Bogorad, M., Wagster, M.V., Phelps, C.H., 2011. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's Dement. 7, 280–292.

Strozyk, D., Blennow, K., White, L.R., Launer, L.J., 2003. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652–656.

Trouche, S.G., Asuni, A., Rouland, S., Wisniewski, T., Frangione, B., Verdier, J.M., Sigurdsson, E.M., Mestre-Frances, N., 2009. Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives. Vaccine 27, 957–964.

Walsh, D.M., Tseng, B.P., Rydel, R.E., Podlisny, M.B., Selkoe, D.J., 2000. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 10831–10839.

Wang, A., Das, P., Switzer 3rd, R.C., Golde, T.E., Jankowsky, J.L., 2011. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J. Neurosci. 31, 4124–4136.

West, M.J., Slomianka, L., Gundersen, H.J.G., 1991. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231, 482–497.

Wiltfang, J., Esselmann, H., Bibl, M., Hull, M., Hampel, H., Kessler, H., Frolich, L., Schroder, J., Peters, O., Jessen, F., Luckhaus, C., Perneczky, R., Jahn, H., Fiszer, M., Maler, J.M., Zimmermann, R., Bruckmoser, R., Kornhuber, J., Lewczuk, P., 2007. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J. Neurochem. 101, 1053–1059.

Winton, M.J., Lee, E.B., Sun, E., Wong, M.M., Leight, S., Zhang, B., Trojanowski, J.Q., Lee, V.M., 2011. Intraneuronal APP, not free Abeta peptides in 3xTg-AD mice: implications for tau versus Abeta-mediated Alzheimer neurodegeneration. J. Neurosci. 31, 7691–7699.

Wirths, O., Dins, A., Bayer, T.A., 2012. AbetaPP accumulation and/or intraneuronal amyloid-beta accumulation? The 3xTg-AD mouse model revisited. J. Alzheimers Dis. 28, 897–904.

Wirths, O., Multhaup, G., Czech, C., Blanchard, V., Moussaoui, S., Tremp, G., Pradier, L., Beyreuther, K., Bayer, T.A., 2001. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 306, 116–120.

Wirths, O., Multhaup, G., Bayer, T.A., 2004. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide–the first step of a fatal cascade. J. Neurochem. 91, 513–520.

Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., Terasaki, T., Hashimoto, T., Iwatsubo, T., 2009. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J. Neurosci. 29, 11393–11398.